Cell MedX (Cell MedX) EBIT per Share : $-0.00 (TTM As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cell MedX EBIT per Share?

Cell MedX's EBIT per Share for the three months ended in Feb. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was 28.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 23.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cell MedX's EBIT per Share or its related term are showing as below:

CMXC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -220.8 Med: 13.3 Max: 39.6
Current: 28.3

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Cell MedX was 39.60% per year. The lowest was -220.80% per year. And the median was 13.30% per year.

CMXC's 3-Year EBIT Growth Rate is ranked better than
77.46% of 723 companies
in the Medical Devices & Instruments industry
Industry Median: 5.7 vs CMXC: 28.30

Cell MedX's EBIT for the three months ended in Feb. 2024 was $0.13 Mil.

Cell MedX EBIT per Share Historical Data

The historical data trend for Cell MedX's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX EBIT per Share Chart

Cell MedX Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

EBIT per Share

Get a 7-Day Free Trial

-0.02

-0.01

Cell MedX Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Cell MedX EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cell MedX's EBIT per Share for the fiscal year that ended in May. 2023 is calculated as

	EBIT per Share		(A: May. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.448	/	62.923
=	-0.01

Cell MedX's EBIT per Share for the quarter that ended in Feb. 2024 is calculated as

	EBIT per Share		(Q: Feb. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.13	/	220.862
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

Cell MedX (OTCPK:CMXC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cell MedX EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cell MedX's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell MedX (Cell MedX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706

Website

https://www.cellmedx.com

Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.

Executives

Richard Jeffs	10 percent owner	FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz	director, officer: Chief Executive Officer	SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves	10 percent owner	904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty	director, officer: CEO, CFO, Treas., Sec	4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta	director, officer: COO	#810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams	director	7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen	director, officer: CEO	635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson	officer: Chief Medical Officer	9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina	officer: CFO, Treasurer and Secretary	789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett	10 percent owner	121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer	director, officer: Chief Technology Officer	C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson • 11-11-2016